- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit
May 14th 2020, 1:11am
People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.
Cancer Mortality Rate Declined More Steeply in States That Expanded Medicaid Under the Affordable Care Act
May 14th 2020, 1:00am
The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.
Video Conference Visits Effective in Reducing Stress, Anxiety in Caregivers for Patients with Cancer
May 14th 2020, 1:00am
The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.
Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer
May 13th 2020, 9:00pm
Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.
Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer
May 13th 2020, 9:00pm
Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.
PARP Inhibitor Trials Revolutionize Frontline Ovarian Cancer
May 4th 2020, 4:30pm
PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.
Innovative Combo Regimens Are Necessary in Heterogeneous Ovarian Cancer Population
May 3rd 2020, 3:47pm
PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.
Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment
May 3rd 2020, 12:40am
PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.
Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment
May 2nd 2020, 8:23pm
PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.
Dr. Slomovitz on Sequencing Strategies in Endometrial Cancer
May 2nd 2020, 6:00pm
PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.
COM701 Shows Early Promise as Monotherapy and Combined With Nivolumab in Advanced Solid Tumors
April 30th 2020, 2:39am
COM701, a novel, first-in-class immune checkpoint inhibitor, was found to demonstrate encouraging preliminary antitumor activity and good tolerability when used as either a monotherapy and in combination with nivolumab in a number of heavily pretreated patients with advanced or metastatic solid tumors, according to data from a phase 1 trial.
Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ Melanoma
April 30th 2020, 2:29am
Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.
RAF-MEK Inhibitor/Defactinib Combo Is Active in KRAS-Mutant Cancers
April 30th 2020, 2:25am
The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.
Cell-Free DNA Detects Adjuvant MRD Positivity and Disease Relapse in NSCLC
April 29th 2020, 8:46pm
Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.
cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin
April 29th 2020, 4:11am
A cell-free DNA test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas study presented at the 2020 AACR Virtual Annual Meeting I.
TERAVOLT Data Reveal "Unexpectedly High" Mortality in Patients With Thoracic Cancers and COVID-19
April 29th 2020, 3:45am
Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population.
Blood Test Is Feasible for Early Detection Across Multiple Cancers
April 29th 2020, 3:40am
A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.
COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond
April 29th 2020, 2:40am
Paolo A. Ascierto, MD, discussed lessons he has learned from the COVID-19 crisis both in the melanoma treatment paradigm and in the broader immuno-oncology spectrum.
TIL Therapy Elicits Encouraging Activity in Advanced NSCLC
April 29th 2020, 2:22am
Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).
Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer
April 29th 2020, 1:52am
Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.